Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Streptococcus Salivarius Evol12® in Improving Quality of Life in Locally Advanced Head and Neck Cancer Treated With Radio(Chemo)Therapy: SMILE (SMILE)

18 novembre 2026 mis à jour par: Aurora Mirabile, IRCCS San Raffaele

Streptococcus Salivarius Evol12® in Improving Quality of Life In Locally Advanced Head and Neck Cancer Treated With radiochEmotherapy: SMILE, a Monocentric National Randomized Double Blind Interventional Study

The clinical study will involve the use of a dietary supplement based on the oral probiotic strain Streptococcus salivarius Evol12® in patients with head and neck cancer undergoing radiochemotherapy, with the aim of improving their quality of life. The hypothesis is that, as already outlined in scientific literature, modifying the oral microbiota through the use of the commensal S. salivarius, increasing its concentration and reducing the main pathogens in the oral cavity, may protect these patients and reduce the impact on their quality of life . A discovery of this kind would allow patients with head and neck cancer to be treated not only with standard therapy but also with treatments designed to modify the oral microbiota, which is not currently taken into consideration, in order to improve these patients' quality of life and compliance with treatment. Compared to the S. salivarius K12 strain, the S. salivarius eK12 (Evol12®) strain has a genome that is entirely similar to K12, but with a hypothetically greater antibacterial activity due to the presence of two specific genetic differences which allow for increased release of a bacteriocin: the salivabactin. Streptococcus salivarius eK12 (Evol12®) has undergone mutagenesis, acute toxicity, and subchronic toxicity studies in animals, conducted according to OECD guidelines by a GLPcertified laboratory, confirming its safety of use and absence of toxicity (In vitro and In vivo safety evaluation of Streptococcus salivarius eK12, a genetically modified dietary probiotic derived from the oral probiotic S. salivarius K12). In addition, a randomized, double-blind, placebo-controlled clinical trial conducted in healthy adults has been published, demonstrating its complete safety of use even at high dosages.

Aperçu de l'étude

Statut

Pas encore de recrutement

Type d'étude

Interventionnel

Inscription (Estimé)

170

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Aurora Mirabile Medical oncologist
  • Numéro de téléphone: +39 02 2643 3526
  • E-mail: mirabile.aurora@hsr.it

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Participants are willing and able to give informed consent for participation in the study.
  2. Aged >=18 years
  3. Patients diagnosed with non-metastatic head and neck malignant tumors, with an Eastern Cooperative Oncology Group performance status of ≤2, planning to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.
  4. Patient affected by squamocellular carcinoma of oral cavity, larynx, hypopharynx, oropharynx and undifferentiated or squamocellular carcinoma of nasopharynx.
  5. Patients eligible for to receive definitive RT or postoperative adjuvant RT concomitant to cisplatin.

Exclusion Criteria:

  1. Patients with a history of allergy to probiotics or severe allergic constitution
  2. Use of antibiotics/antifungal drugs within 1 month or antimicrobial mouthwash within 1 week before the study
  3. Poor oral hygiene and/or severe periodontal diseases (CTCAE 5.0 Grading >/=2)
  4. Any previous RT to the head and neck region
  5. Those deemed unsuitable for the study by the investigators (concomitant with any other severe diseases)
  6. Allergies: history of known allergies to probiotics or to product excipients.
  7. Recent antimicrobial therapies: use of systemic antibiotics or antifungals within 1 month, or antimicrobial mouthwashes within 1 week.
  8. Oral cavity conditions: severely compromised oral hygiene or severe periodontal disease.
  9. Previous radiotherapy: any prior radiotherapy (RT) to the head and neck region.
  10. Severe comorbidities: severe concomitant diseases that make the patient unsuitable according to clinical judgment.
  11. Pregnancy and breastfeeding
  12. Contraindication related to probiotic composition
  13. Primary sites different from the ones described in inclusion criteria
  14. Patient unfit to cisplatin
  15. Immunocompromised Patients

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Soins de soutien
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: placebo group

The placebo lozenges will be identical in appearance, taste, and composition, but will contain only excipients (sugar and starch), without any active bacteria.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration

Expérimental: group treated with probiotic: Streptococcus salivarius Evol12®

The investigational product (Bactoblis® Evol, containing the probiotic strain Streptococcus salivarius Evol12®) will be provided in the form of oral lozenges, each containing ≥ 1 × 10⁹ colony-forming units (CFU) of viable S. salivarius Evol12® cells as the active ingredient.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period.

Participants will be instructed to slowly dissolve one lozenge in the mouth three times daily (morning, afternoon, and evening) throughout the entire radiotherapy (RT) period. Patients will also be advised to avoid eating, drinking, or performing oral hygiene procedures for at least one hour after administration, in order to ensure optimal mucosal contact and promote probiotic colonization.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
EORTC QLQ-H&N35 score
Délai: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in quality of life assessed using the EORTC QLQ-H&N35 scale before treatment, 3 weeks, at the end of treatment (8 weeks) and thereafter for up to 8 weeks.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
days
Délai: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Time to onset (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
Délai: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Duration (days) of WHO grade ≥2 and ≥3.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
Délai: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Rate of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Numeric Rating Scale (NRS)
Délai: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Change in Pain Scores Over Time, assessed using the Numeric Rating Scale (NRS; 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
Percentage
Délai: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Percentage of patients requiring enteral or parenteral nutritional support according to the percentage of weight loss (≥5% o ≥10%).

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.
days
Délai: It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

duration of RT/chemotherapy interruptions, dose reduction or delay due to toxicity.

It will be assessed before treatment, 3 weeks, 8 weeks and subsequently for up to 8 weeks.

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

1 janvier 2027

Achèvement de l'étude (Estimé)

1 décembre 2028

Dates d'inscription aux études

Première soumission

4 novembre 2026

Première soumission répondant aux critères de contrôle qualité

18 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner